<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104211">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01927861</url>
  </required_header>
  <id_info>
    <org_study_id>GHLIQUID-4020</org_study_id>
    <secondary_id>U1111-1131-5892</secondary_id>
    <nct_id>NCT01927861</nct_id>
  </id_info>
  <brief_title>Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome</brief_title>
  <official_title>A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia. The aim of this trial is to investigate the long-term
      efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan
      syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in height SDS (Standard Deviation Score)</measure>
    <time_frame>Week 0, week 104</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in height SDS (Standard Deviation Score)</measure>
    <time_frame>Week 0, week 208</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (AEs)</measure>
    <time_frame>Weeks 0, Week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (AEs)</measure>
    <time_frame>Weeks 0, Week 208</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF-I (insulin like growth factor I)</measure>
    <time_frame>Week 0, week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF-I (insulin like growth factor I)</measure>
    <time_frame>Week 0, week 208</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (Glycosylated haemoglobin)</measure>
    <time_frame>Week 0, week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (Glycosylated haemoglobin)</measure>
    <time_frame>Week 0, week 208</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Genetic Disorder</condition>
  <condition>Noonan Syndrome</condition>
  <arm_group>
    <arm_group_label>0.033 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.066 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.</description>
    <arm_group_label>0.033 mg/kg/day</arm_group_label>
    <arm_group_label>0.066 mg/kg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese children with Noonan syndrome clinically diagnosed in one of the following
             ways: 1. Clinically diagnosed by at least two medical experts using van der Burgt
             score list, 2. Clinically diagnosed by one medical expert using van der Burgt score
             list and diagnosed by result of genetic testing for Noonan syndrome, 3. Clinically
             diagnosed by one medical expert using van der Burgt score list and diagnosed by the
             same medical expert based on the results of centralised evaluation of facial change
             using van der Burgt score list

          -  Height SDS (standard deviation score): -2 SDS or below (according to the Japanese
             reference data)

          -  Age: boys 3 to below 11 years, girls 3 to below 10 years

          -  Height records must be available within the period between 40 and 64 weeks prior to
             Visit 1 (screening)

          -  Prepubertal children (definition for girls breast and pubes of Tanner stage is I, and
             none of menses, and for boys testicular volume below 4 mL, and pubes and penis of
             Tanner stage is I)

        Exclusion Criteria:

          -  Children with known or suspected hypersensitivity against human growth hormone (hGH)
             or related products (including any components of the trial products)

          -  Children with diabetic type diagnosed with the Japanese Diabetes Society
             Classification

          -  Children with history or presence of active malignancy

          -  Children who have received GH (growth hormone) treatment

          -  Children who have received systemic administration of the following medications
             within two years prior to Visit 1 (screening): Thyroid hormone (except replacement
             therapy), antithyroid hormone, androgen, oestrogen, progesterone, anabolic steroid,
             adrenocortical steroid treatment period for at least 13 weeks), derivative of
             gonadotropin releasing hormone and somatomedin C (IGF-I)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Saitama-city, Saitama</city>
        <zip>336-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>August 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Noonan Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
